DBV Technologies Welcomes Dr. Philina Lee to Its Board

Leadership Changes at DBV Technologies

DBV Technologies, a prominent clinical-stage biopharmaceutical company, has announced an exciting addition to its Board of Directors. The company has recently appointed Dr. Philina Lee as an independent director, replacing Daniel Soland. This provisional appointment is subject to ratification by shareholders at the next annual meeting. With this change, the board will now consist of ten members.

Philina Lee's Expertise

Dr. Philina Lee comes to DBV Technologies with an impressive background in the biopharmaceutical sector. She has demonstrated her leadership capabilities at Blueprint Medicines, where she rose through the ranks to become the Chief Commercial Officer. In this role, she was instrumental in launching and growing the drug AYVAKIT®. Moreover, she has served on the Board of Directors for Fusion Pharmaceuticals, contributing to vital committees that influence the strategic direction of the company.

Company's Commitment to Allergy Treatment

Dr. Lee expressed her excitement over joining the board during a crucial phase for DBV Technologies, especially as they advance their innovative treatment VIASKIN® Peanut, targeting children and toddlers affected by peanut allergies. She stated her intent to contribute significantly to the company’s growth and the successful outcomes of its projects.

About DBV Technologies

DBV Technologies is dedicated to creating groundbreaking treatments for food allergies and other immunological conditions, addressing significant unmet medical needs. The company is particularly focused on its proprietary VIASKIN® patch technology, designed to treat food allergies through epicutaneous immunotherapy (EPIT). This innovative approach allows microgram quantities of biologically active compounds to penetrate the immune system via the skin, promoting a desensitization effect by retraining the immune response.

Current Clinical Trials

The company is currently conducting clinical trials using the VIASKIN® patch for toddlers aged 1 to 3 years and children aged 4 to 7 years who suffer from peanut allergies. This reflects DBV Technologies’ commitment to transforming the lives of individuals affected by food allergies, particularly among the pediatric population.

Headquarters and Operations

DBV Technologies operates globally, with its headquarters in France and additional operations based in Warren, New Jersey. The company’s ordinary shares are listed on segment B of Euronext Paris under the ticker DBV, while its American Depository Shares are traded on the Nasdaq Capital Market under the ticker DBVT.

Investor Relations

For inquiries, investors can reach out to Katie Matthews via email at katie.matthews@dbv-technologies.com. Additionally, media inquiries should be directed to Brett Whelan at brett.whelan@dbv-technologies.com. DBV Technologies remains dedicated to keeping stakeholders informed as it evolves and progresses in the development of its innovative therapies.

Frequently Asked Questions

What recent changes has DBV Technologies made to its board?

DBV Technologies has appointed Dr. Philina Lee as an independent director to its Board, replacing Daniel Soland.

What is Dr. Philina Lee's background?

Dr. Lee has significant experience in the biopharmaceutical industry, previously serving as Chief Commercial Officer at Blueprint Medicines.

What is VIASKIN®?

VIASKIN® is a patch technology developed by DBV Technologies, aimed at treating food allergies through a non-invasive epicutaneous immunotherapy method.

Who can benefit from DBV's treatments?

DBV Technologies focuses on treating children and toddlers who suffer from food allergies, particularly peanut allergies.

How can investors contact DBV Technologies?

Investors can contact DBV Technologies’ investor relations team through Katie Matthews at her provided email address.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.